Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of Multiple Doses of Convalescent Plasma in Intubated COVID-19 Patients
NCT05595538Phase 1Completed
- Sponsor
- Hospital Regional Dr. Rafael Estévez
- Start
- Jun 2020
- Primary completion
- Sep 2020
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of convalescent plasma (Heinrich-Heine University, Duesseldorf) in coronavirus disease 2019 (COVID-19), sponsored by Hospital Regional Dr. Rafael Estévez. Primary endpoint: Percentage of participants who received at least one unit more than one day at 8 days. Started Jun 2020; status: completed.
02
Drugs
convalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05595538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05595538.